Table 2.
Efficacy outcomes.
| Chemotherapy doublet plus targeted therapy by RAS status (n = 126) | Chemotherapy triplet plus targeted therapy by RAS status (n = 130) | |
|---|---|---|
| Variable | ||
| R0/R1 resection, n (%, 95% CI) | 61 (48.4, 39–57) | 74 (56.9, 48–66) |
| 8-week overall response, n (%, 95% CI) | 60 (50.4, 41.1–659.7) | 69 (57.4, 48.1–66.3) |
| Complete response, n (%) | 1 (0.8) | 2 (1.7) |
| Partial response, n (%) | 59 (49.6) | 68 (56.2) |
| Stable disease, n (%) | 52 (43.7) | 48 (39.7) |
| Progressive disease, n (%) | 7 (5.9) | 3 (2.5) |
| Unknown, n | 7 | 7 |
| Best overall response, n (%, 95% CI) | 83 (65.9, 56.9–74.1) | 96 (75.0, 66.6–82.2) |
| Complete response, n (%) | 20 (16.8) | 25 (20.7) |
| Partial response, n (%) | 63 (52.9) | 71 (58.7) |
| Stable disease, n (%) | 31 (26.1) | 22 (18.2) |
| Progressive disease, n (%) | 5 (4.2) | 3 (2.5) |
| Unknown, n | 7 | 7 |
| Progression-free survival time | ||
| Median (95% CI), months | 11.5 (10.2–13.0) | 13.1 (11.3–13.8) |
| Overall survival time | ||
| Median (95% CI), months | 40.4 (34.4–46.5) | 43.4 (36.7–49.4) |